Go Pro
→ Solar lost. Wind lost. One won. (From Behind the Markets) (Ad)tc pixel Free OFIX Stock Alerts

Orthofix Medical (OFIX) Financials

Orthofix Medical logo
$11.79 +0.16 (+1.38%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$11.80 +0.01 (+0.04%)
As of 07/13/2026 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Orthofix Medical

Annual Income Statements for Orthofix Medical

This table shows Orthofix Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.81 3.06 6.22 14 -28 2.52 -38 -20 -151 -126 -92
Consolidated Net Income / (Loss)		 -2.81 3.06 6.22 14 -28 2.52 -38 -20 -151 -126 -92
Net Income / (Loss) Continuing Operations		 -2.34 3.50 7.29 14 -28 2.52 -38 -20 -151 -126 -92
Total Pre-Tax Income 		8.51 19 36 23 -27 -0.37 -13 -18 -149 -124 -91
Total Operating Income		 9.26 21 41 30 -19 -6.27 -8.32 -13 -139 -85 -81
Total Gross Profit		 310 322 341 356 359 305 350 337 486 546 566
Total Revenue		 396 410 434 453 460 407 464 461 747 799 822
Operating Revenue		 396 410 434 453 460 407 464 461 747 799 822
Total Cost of Revenue		 87 88 93 97 101 102 115 124 260 254 256
Operating Cost of Revenue		 87 88 93 97 101 102 115 124 260 254 256
Total Operating Expenses		 301 301 300 326 378 311 358 350 625 631 647
Selling, General & Admin Expense		 87 76 72 83 86 68 69 309 530 533 554
Research & Development Expense		 26 29 30 33 35 39 50 49 80 74 66
Amortization Expense		 - - - 4.32 34 -0.50 18 -7.40 15 24 27
Total Other Income / (Expense), net		 -0.75 -2.04 -4.42 -7.21 -8.27 5.90 -5.18 -4.44 -9.57 -39 -9.38
Interest Expense		 0.49 -0.76 0.42 0.83 0.12 2.48 1.84 1.29 8.63 30 17
Other Income / (Expense), net		 -0.26 -2.81 -4.00 -6.38 -8.14 8.38 -3.34 -3.15 -0.94 -9.63 8.11
Income Tax Expense		 11 16 29 9.07 1.41 -2.89 25 2.04 2.72 2.12 1.38
Basic Earnings per Share		 ($0.15) $0.17 $0.34 $0.73 ($1.51) $0.13 ($1.95) ($0.98) ($4.12) ($3.30) ($2.33)
Weighted Average Basic Shares Outstanding		 18.80M 18.14M 18.12M 18.49M 18.90M 19.27M 19.69M 20.05M 36.73M 38.13M 39.60M
Diluted Earnings per Share		 ($0.15) $0.17 $0.34 $0.72 ($1.51) $0.13 ($1.95) ($0.98) ($4.12) ($3.30) ($2.33)
Weighted Average Diluted Shares Outstanding		 18.80M 18.46M 18.50M 18.91M 18.90M 19.39M 19.69M 20.05M 36.73M 38.13M 39.60M
Weighted Average Basic & Diluted Shares Outstanding		 18.70M 18M 18.30M 18.90M 19.18M 19.51M 19.85M 36.46M 37.41M 39.02M 40.14M

Quarterly Income Statements for Orthofix Medical

This table shows Orthofix Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -29 -22 -36 -33 -27 -29 -53 -14 -23 -2.22 -21
Consolidated Net Income / (Loss)		 -29 -22 -36 -33 -27 -29 -53 -14 -23 -2.22 -21
Net Income / (Loss) Continuing Operations		 -29 -22 -36 -33 -27 -29 -53 -14 -23 -2.22 -21
Total Pre-Tax Income 		-28 -22 -35 -32 -27 -30 -52 -14 -22 -2.19 -21
Total Operating Income		 -24 -18 -29 -25 -19 -11 -49 -16 -17 0.49 -14
Total Gross Profit		 120 137 127 135 135 149 122 140 149 156 140
Total Revenue		 184 199 189 199 197 216 194 203 206 220 197
Operating Revenue		 184 199 189 199 197 216 194 203 206 220 197
Total Cost of Revenue		 64 64 61 64 62 67 72 64 57 64 57
Operating Cost of Revenue		 64 64 61 64 62 67 72 64 57 64 57
Total Operating Expenses		 144 155 157 160 154 160 170 156 166 156 154
Selling, General & Admin Expense		 27 420 132 134 130 433 133 136 148 137 135
Research & Development Expense		 19 19 19 18 17 19 20 16 15 15 15
Amortization Expense		 3.57 3.72 5.40 7.39 6.52 5.03 18 3.11 2.69 3.72 3.75
Total Other Income / (Expense), net		 -3.94 -3.73 -5.83 -7.45 -7.74 -18 -3.26 1.78 -5.22 -2.69 -6.40
Interest Expense		 1.58 4.50 4.56 4.94 5.21 15 4.51 3.95 4.68 4.35 5.66
Other Income / (Expense), net		 -2.36 0.77 -1.27 -2.51 -2.53 -3.31 1.25 5.73 -0.54 1.67 -0.73
Income Tax Expense		 0.47 0.13 0.85 1.08 0.75 -0.56 0.96 -0.14 0.53 0.03 0.07
Basic Earnings per Share		 ($0.77) ($0.57) ($0.95) ($0.88) ($0.71) ($0.76) ($1.35) ($0.36) ($0.57) ($0.05) ($0.52)
Weighted Average Basic Shares Outstanding		 37.25M 36.73M 37.74M 38.02M 38.49M 38.13M 39.19M 39.50M 39.77M 39.60M 40.45M
Diluted Earnings per Share		 ($0.77) ($0.57) ($0.95) ($0.88) ($0.71) ($0.76) ($1.35) ($0.36) ($0.57) ($0.05) ($0.52)
Weighted Average Diluted Shares Outstanding		 37.25M 36.73M 37.74M 38.02M 38.49M 38.13M 39.19M 39.50M 39.77M 39.60M 40.45M
Weighted Average Basic & Diluted Shares Outstanding		 36.76M 37.41M 37.53M 38.17M 38.21M 39.02M 39.18M 39.49M 39.60M 40.14M 40.42M

Annual Cash Flow Statements for Orthofix Medical

This table details how cash moves in and out of Orthofix Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 27 -9.72 27 -8.97 -1.79 26 -8.97 -37 -13 48 -0.62
Net Cash From Operating Activities		 44 59 39 50 32 74 18 -12 -46 26 33
Net Cash From Continuing Operating Activities		 44 59 39 50 32 74 18 -12 -46 26 33
Net Income / (Loss) Continuing Operations		 -2.81 3.06 6.22 14 -28 2.52 -38 -20 -151 -126 -92
Consolidated Net Income / (Loss)		 -2.81 3.06 6.22 14 -28 2.52 -38 -20 -151 -126 -92
Depreciation Expense		 21 21 20 19 25 31 30 29 53 60 77
Amortization Expense		 1.75 1.57 1.71 1.02 3.78 3.73 3.50 3.06 44 28 5.93
Non-Cash Adjustments To Reconcile Net Income		 10 21 21 23 30 14 32 37 65 74 65
Changes in Operating Assets and Liabilities, net		 13 13 -10 -6.59 2.49 23 -8.02 -61 -56 -10 -22
Net Cash From Investing Activities		 -38 -22 -16 -61 -23 -52 -23 -25 -33 -28 -35
Net Cash From Continuing Investing Activities		 -38 -22 -16 -61 -23 -52 -23 -25 -33 -28 -35
Purchase of Property, Plant & Equipment		 -27 -16 -15 -14 -19 -15 -18 -23 -62 -35 -35
Divestitures		 - - 0.47 - - - 0.00 0.00 29 0.00 0.00
Sale and/or Maturity of Investments		 - - - - - - - 0.13 0.00 7.40 0.00
Other Investing Activities, net		 - -3.61 - - - - -1.25 0.00 -0.50 -0.10 0.03
Net Cash From Financing Activities		 25 -46 3.54 2.99 -11 3.25 -3.62 -0.08 65 51 -0.79
Net Cash From Continuing Financing Activities		 25 -46 3.54 2.99 -11 3.25 -3.62 -0.08 65 51 -0.79
Repayment of Debt		 -1.83 - -0.45 -0.68 -3.02 -102 -0.95 -0.09 -81 -146 -0.53
Payment of Dividends		 - - - - - - 0.00 0.00 -27 0.00 0.00
Issuance of Debt		 34 - - 0.00 0.00 100 0.00 0.00 175 198 0.00
Issuance of Common Equity		 5.25 20 7.78 7.10 12 7.60 8.82 4.34 5.13 6.26 5.93
Other Financing Activities, net		 -1.55 -2.41 -3.80 -3.43 -19 -2.82 -11 -4.32 -6.05 -7.02 -6.18
Effect of Exchange Rate Changes		 -3.14 -0.74 1.18 -0.88 -0.21 1.24 -0.82 -1.00 0.62 -0.94 1.41

Quarterly Cash Flow Statements for Orthofix Medical

This table details how cash moves in and out of Orthofix Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -3.94 4.09 -8.29 -0.60 3.69 53 -25 8.24 -2.74 19 36
Net Cash From Operating Activities		 0.48 -6.69 -19 8.98 12 24 -18 12 12 28 -18
Net Cash From Continuing Operating Activities		 0.48 -6.69 -19 8.98 12 24 -18 12 12 28 -18
Net Income / (Loss) Continuing Operations		 -29 -22 -36 -33 -27 -29 -53 -14 -23 -2.22 -21
Consolidated Net Income / (Loss)		 -29 -22 -36 -33 -27 -29 -53 -14 -23 -2.22 -21
Depreciation Expense		 13 14 15 14 15 16 34 17 13 13 13
Amortization Expense		 9.11 10 4.53 4.56 4.66 14 1.25 1.13 1.58 1.98 1.06
Non-Cash Adjustments To Reconcile Net Income		 15 7.07 18 25 17 14 22 19 13 11 10
Changes in Operating Assets and Liabilities, net		 -7.97 -16 -20 -1.32 2.21 8.39 -22 -12 7.90 3.83 -22
Net Cash From Investing Activities		 -22 -15 -11 -9.72 -5.86 -1.14 -6.74 -7.10 -9.89 -11 -11
Net Cash From Continuing Investing Activities		 -22 -15 -11 -9.72 -5.86 -1.14 -6.74 -7.10 -9.89 -11 -11
Purchase of Property, Plant & Equipment		 -22 -16 -11 -9.34 -5.32 -9.67 -6.74 -7.11 -9.90 -11 -11
Other Investing Activities, net		 - - -0.05 - -0.05 - 0.00 0.01 0.01 0.01 0.15
Net Cash From Financing Activities		 18 25 21 0.23 -2.46 31 -0.65 2.64 -5.15 2.38 64
Net Cash From Continuing Financing Activities		 18 25 21 0.23 -2.46 31 -0.65 2.64 -5.15 2.38 64
Repayment of Debt		 -0.42 -55 -17 -0.85 -0.23 -129 -0.51 -0.02 - - -0.02
Issuance of Debt		 19 105 40 - - 158 0.00 - - - 64
Issuance of Common Equity		 - 2.75 0.00 3.19 0.12 2.95 0.05 3.01 0.04 2.84 0.00
Other Financing Activities, net		 -0.33 -0.31 -2.00 -2.12 -2.35 -0.55 -0.19 -0.35 -5.19 -0.46 -0.03
Effect of Exchange Rate Changes		 -0.33 0.56 -0.28 -0.09 0.34 -0.90 0.49 1.05 -0.10 -0.03 -0.09

Annual Balance Sheets for Orthofix Medical

This table presents Orthofix Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 400 372 405 467 496 526 477 459 925 893 851
Total Current Assets		 212 194 252 245 261 270 270 256 420 433 417
Cash & Equivalents		 64 40 81 70 70 96 88 51 33 83 82
Restricted Cash		 - 14 - 2.57 0.68 0.53 - 0.00 4.65 2.50 3.09
Accounts Receivable		 60 58 63 78 87 72 79 83 128 135 136
Inventories, net		 58 63 81 77 82 85 83 100 222 189 172
Prepaid Expenses		 31 19 26 18 21 17 20 22 32 23 24
Plant, Property, & Equipment, net		 52 49 45 43 63 64 59 58 159 140 129
Total Noncurrent Assets		 136 129 108 179 172 192 148 144 346 320 304
Goodwill		 54 54 54 72 71 84 71 71 195 195 195
Intangible Assets		 5.30 7.46 10 52 54 61 53 47 117 99 73
Noncurrent Deferred & Refundable Income Taxes		 57 47 23 33 35 25 - - - - 0.00
Other Noncurrent Operating Assets		 19 20 21 22 12 22 24 26 33 26 37
Total Liabilities & Shareholders' Equity		 400 372 405 467 496 526 477 459 925 893 851
Total Liabilities		 110 109 109 131 168 169 140 122 327 390 401
Total Current Liabilities		 82 83 79 86 85 104 106 84 165 169 170
Accounts Payable		 16 14 18 18 20 23 26 28 58 49 58
Other Current Liabilities		 66 69 61 68 65 81 79 56 106 120 112
Total Noncurrent Liabilities		 28 25 29 45 83 65 34 38 161 222 230
Long-Term Debt		 - - - - - - - 0.00 93 157 157
Other Noncurrent Operating Liabilities		 28 25 29 45 83 65 34 38 68 65 73
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 290 263 297 335 328 357 337 337 599 503 450
Total Preferred & Common Equity		 290 263 297 335 328 357 337 337 599 503 450
Total Common Equity		 290 263 297 335 328 357 337 337 599 503 450
Common Stock		 234 206 222 245 273 294 316 337 750 784 818
Retained Earnings		 63 64 70 87 58 59 21 1.25 -150 -276 -368
Accumulated Other Comprehensive Income / (Loss)		 -6.23 -6.58 3.79 3.30 -3.04 3.25 0.00 -1.38 -1.29 -4.30 0.62

Quarterly Balance Sheets for Orthofix Medical

This table presents Orthofix Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 450 917 901 906 906 882 868 823 837 833 887
Total Current Assets		 247 410 399 394 399 386 386 390 396 394 462
Cash & Equivalents		 52 50 38 34 27 26 30 58 66 63 120
Restricted Cash		 - - - - 2.50 2.50 2.50 2.50 3.08 3.09 0.59
Accounts Receivable		 76 113 112 114 126 125 125 132 130 131 138
Inventories, net		 100 222 222 222 219 210 206 174 173 174 178
Prepaid Expenses		 19 25 27 24 25 22 23 24 25 23 25
Plant, Property, & Equipment, net		 58 137 141 153 158 154 147 131 129 130 125
Total Noncurrent Assets		 145 370 361 359 349 342 335 302 312 308 300
Goodwill		 71 203 192 195 195 195 195 195 195 195 195
Intangible Assets		 48 122 126 121 113 108 105 81 79 76 69
Noncurrent Deferred & Refundable Income Taxes		 1.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets		 25 45 44 43 41 39 35 26 38 38 35
Total Liabilities & Shareholders' Equity		 450 917 901 906 906 882 868 823 837 833 887
Total Liabilities		 116 253 261 290 336 336 342 365 379 390 451
Total Current Liabilities		 78 138 142 153 151 156 162 144 148 160 161
Accounts Payable		 28 46 51 53 57 50 47 45 45 50 55
Other Current Liabilities		 50 92 90 99 90 101 109 99 103 109 106
Total Noncurrent Liabilities		 38 115 119 138 185 180 180 221 230 230 290
Long-Term Debt		 - 45 51 70 115 113 112 157 157 157 221
Other Noncurrent Operating Liabilities		 38 70 68 68 70 67 68 64 73 73 69
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 334 664 640 615 570 546 526 458 458 442 435
Total Preferred & Common Equity		 334 664 640 615 570 546 526 458 458 442 435
Total Common Equity		 334 664 640 615 570 546 526 458 458 442 435
Common Stock		 330 725 739 745 757 768 774 790 801 808 824
Retained Earnings		 8.31 -60 -99 -128 -186 -220 -247 -329 -343 -366 -389
Accumulated Other Comprehensive Income / (Loss)		 -5.16 -0.95 -0.11 -1.86 -0.66 -2.73 -0.90 -2.56 0.91 0.63 0.14

Annual Metrics And Ratios for Orthofix Medical

This table displays calculated financial ratios and metrics derived from Orthofix Medical's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 18,889,815.00 17,826,136.00 18,231,334.00 18,920,827.00 19,055,154.00 19,333,698.00 19,745,269.00 - - - 39,599,659.00
DEI Adjusted Shares Outstanding		 18,889,815.00 17,826,136.00 18,231,334.00 18,920,827.00 19,055,154.00 19,333,698.00 19,745,269.00 - - - 39,599,659.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.15 0.17 0.34 0.73 -1.49 0.13 -1.94 - - - -2.33
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -1.44% 3.35% 5.87% 4.43% 1.53% -11.61% 14.25% -0.81% 61.77% 7.27% 2.85%
EBITDA Growth		 -22.26% 28.42% 44.19% -26.00% -96.43% 2,247.81% -41.09% -26.96% -377.47% 85.97% 263.00%
EBIT Growth		 -36.83% 102.99% 101.56% -35.57% -213.55% 107.85% -651.21% -40.83% -753.02% 32.71% 22.20%
NOPAT Growth		 50.53% 251.99% 111.14% 122.12% -172.40% 66.64% -32.70% -59.57% -948.46% 39.17% 3.77%
Net Income Growth		 67.10% 208.79% 103.63% 121.93% -306.08% 108.84% -1,624.79% 48.54% -666.60% 16.78% 26.83%
EPS Growth		 67.39% 213.33% 100.00% 111.76% -309.72% 108.61% -1,600.00% 49.74% -320.41% 19.90% 29.39%
Operating Cash Flow Growth		 -14.76% 35.46% -34.03% 28.09% -35.83% 131.86% -75.13% -162.45% -296.54% 156.37% 29.30%
Free Cash Flow Firm Growth		 -102.73% 2,697.33% -89.22% -1,408.63% 75.78% -0.45% 171.31% -1,002.75% -906.34% 104.65% -122.64%
Invested Capital Growth		 -0.76% -7.55% 2.82% 22.17% -2.27% 1.09% -4.21% 14.88% 129.01% -12.35% -9.07%
Revenue Q/Q Growth		 1.11% 0.96% 1.96% 0.93% 0.09% -0.94% 1.63% -0.61% 11.50% 2.12% 0.52%
EBITDA Q/Q Growth		 697.36% 82.30% 30.05% -11.20% -75.20% 8.51% -42.79% 16.95% 10.42% 59.89% 20.08%
EBIT Q/Q Growth		 126.49% -18.15% 60.51% -18.36% -35.59% 147.37% -432.33% 12.80% -8.35% 2.84% 18.78%
NOPAT Q/Q Growth		 85.25% -61.41% 860.82% 120.84% -79.29% -6.64% 86.21% -14.61% -5.52% 7.48% 12.82%
Net Income Q/Q Growth		 76.54% -68.37% 338.55% 112.22% 9.00% -89.33% -156.80% 56.59% -11.09% -5.86% 22.60%
EPS Q/Q Growth		 76.19% -66.67% 277.78% 111.76% 8.48% -89.26% -261.11% 60.96% -5.64% -6.11% 23.36%
Operating Cash Flow Q/Q Growth		 4.49% 6.51% 30.76% -14.93% -22.21% 16.19% -36.26% -447.60% -24.63% 656.54% 13.50%
Free Cash Flow Firm Q/Q Growth		 92.09% 22.06% 154.12% -7.63% -166.11% 75.82% 110.43% -454.23% -0.93% 190.27% -138.68%
Invested Capital Q/Q Growth		 -2.94% -7.43% -6.89% -1.46% 3.33% -5.30% -11.55% 1.52% 0.54% -6.12% -2.14%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 78.18% 78.56% 78.55% 78.67% 78.13% 74.94% 75.26% 73.18% 65.24% 68.28% 68.83%
EBITDA Margin		 7.99% 9.92% 13.52% 9.58% 0.34% 8.95% 4.62% 3.40% -5.83% -0.76% 1.21%
Operating Margin		 2.33% 5.14% 9.41% 6.64% -4.08% -1.54% -1.79% -2.88% -18.66% -10.58% -9.90%
EBIT Margin		 2.27% 4.46% 8.48% 5.23% -5.85% 0.52% -2.51% -3.56% -18.79% -11.79% -8.92%
Profit (Net Income) Margin		 -0.71% 0.75% 1.43% 3.05% -6.19% 0.62% -8.26% -4.29% -20.31% -15.76% -11.21%
Tax Burden Percent		 -33.02% 16.06% 17.10% 60.35% 105.22% -683.97% 284.39% 111.54% 101.88% 101.71% 101.52%
Interest Burden Percent		 94.56% 104.18% 98.87% 96.51% 100.45% -17.40% 115.76% 107.85% 106.10% 131.44% 123.85%
Effective Tax Rate		 127.53% 81.62% 79.96% 39.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1.12% 1.78% 3.85% 7.59% -5.05% -1.70% -2.29% -3.47% -20.69% -9.63% -10.39%
ROIC Less NNEP Spread (ROIC-NNEP)		 -0.73% 3.16% 6.74% 13.26% 16.43% -9.95% 32.98% 11.63% -1,851.80% -114.05% -59.43%
Return on Net Nonoperating Assets (RNNOA)		 0.17% -0.67% -1.63% -3.22% -3.53% 2.43% -8.78% -2.39% -11.68% -13.24% -8.95%
Return on Equity (ROE)		 -0.95% 1.10% 2.22% 4.37% -8.59% 0.74% -11.06% -5.86% -32.36% -22.87% -19.34%
Cash Return on Invested Capital (CROIC)		 -0.36% 9.62% 1.06% -12.37% -2.75% -2.78% 2.02% -17.32% -99.11% 3.53% -0.90%
Operating Return on Assets (OROA)		 2.27% 4.73% 9.47% 5.44% -5.60% 0.41% -2.33% -3.51% -20.24% -10.36% -8.41%
Return on Assets (ROA)		 -0.71% 0.79% 1.60% 3.17% -5.92% 0.49% -7.66% -4.22% -21.88% -13.86% -10.57%
Return on Common Equity (ROCE)		 -0.95% 1.10% 2.22% 4.37% -8.59% 0.74% -11.06% -5.86% -32.36% -22.87% -19.34%
Return on Equity Simple (ROE_SIMPLE)		 -0.97% 1.16% 2.10% 4.12% -8.69% 0.71% -11.39% -5.86% -25.29% -25.04% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.55 3.87 8.18 18 -13 -4.39 -5.82 -9.29 -97 -59 -57
NOPAT Margin		 -0.64% 0.95% 1.88% 4.01% -2.86% -1.08% -1.25% -2.02% -13.07% -7.41% -6.93%
Net Nonoperating Expense Percent (NNEP)		 -0.39% -1.39% -2.89% -5.67% -21.48% 8.26% -35.26% -15.10% 1,831.12% 104.42% 49.03%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -2.76% -14.05% -8.97% -9.38%
Cost of Revenue to Revenue		 21.82% 21.44% 21.45% 21.33% 21.87% 25.06% 24.74% 26.82% 34.93% 31.72% 31.17%
SG&A Expenses to Revenue		 21.98% 18.65% 16.57% 18.38% 18.61% 16.71% 14.93% 67.02% 71.16% 66.61% 67.41%
R&D to Revenue		 6.66% 7.03% 6.85% 7.33% 7.53% 9.61% 10.68% 10.65% 10.76% 9.21% 8.01%
Operating Expenses to Revenue		 75.84% 73.42% 69.15% 72.03% 82.21% 76.48% 77.05% 76.06% 83.91% 78.86% 78.73%
Earnings before Interest and Taxes (EBIT)		 9.00 18 37 24 -27 2.12 -12 -16 -140 -94 -73
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 32 41 59 43 1.55 36 21 16 -43 -6.09 9.93
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.55 2.45 3.36 2.96 2.69 2.33 1.82 1.22 0.83 1.33 1.33
Price to Tangible Book Value (P/TBV)		 3.20 3.19 4.29 4.70 4.35 3.91 2.88 1.88 1.73 3.19 3.29
Price to Revenue (P/Rev)		 1.87 1.57 2.30 2.19 1.91 2.04 1.32 0.89 0.66 0.83 0.73
Price to Earnings (P/E)		 0.00 211.04 160.25 71.91 0.00 330.14 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.47% 0.62% 1.39% 0.00% 0.30% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.99 2.82 4.25 3.50 3.15 2.82 2.11 1.26 0.84 1.29 1.29
Enterprise Value to Revenue (EV/Rev)		 1.71 1.44 2.11 2.03 1.76 1.81 1.13 0.78 0.74 0.92 0.82
Enterprise Value to EBITDA (EV/EBITDA)		 21.38 14.53 15.62 21.22 522.30 20.17 24.54 23.00 0.00 0.00 67.71
Enterprise Value to EBIT (EV/EBIT)		 75.26 32.36 24.89 38.84 0.00 347.11 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 152.62 112.04 50.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 15.52 10.00 23.51 18.45 25.27 9.88 28.47 0.00 0.00 28.64 20.17
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 28.16 405.07 0.00 0.00 0.00 102.43 0.00 0.00 34.04 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.31 0.35
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.31 0.35
Financial Leverage		 -0.23 -0.21 -0.24 -0.24 -0.22 -0.24 -0.27 -0.21 0.01 0.12 0.15
Leverage Ratio		 1.34 1.39 1.39 1.38 1.45 1.49 1.44 1.39 1.48 1.65 1.83
Compound Leverage Factor		 1.27 1.45 1.37 1.33 1.46 -0.26 1.67 1.50 1.57 2.17 2.27
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.61% 23.79% 25.91%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.18% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.43% 23.79% 25.91%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 86.39% 76.21% 74.09%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.17 -25.77 15.85
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.30 -11.70 7.28
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.14 -25.77 15.85
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.97 -2.65 -2.76
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.58 -1.20 -1.27
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.96 -2.65 -2.76
Altman Z-Score		 5.72 5.42 7.63 6.35 4.48 4.27 4.00 3.37 1.32 1.50 1.32
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.59 2.33 3.17 2.85 3.07 2.60 2.55 3.06 2.54 2.57 2.45
Quick Ratio		 1.51 1.17 1.82 1.72 1.84 1.62 1.57 1.60 0.98 1.29 1.28
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.81 21 2.26 -30 -7.17 -7.20 5.14 -46 -467 22 -4.91
Operating Cash Flow to CapEx		 194.71% 359.52% 265.75% 367.26% 168.62% 479.64% 103.88% -49.82% -73.74% 73.95% 96.31%
Free Cash Flow to Firm to Interest Expense		 -1.65 0.00 5.44 -35.74 -58.76 -2.90 2.80 -35.99 -54.05 0.73 -0.28
Operating Cash Flow to Interest Expense		 89.18 0.00 93.68 60.29 262.57 29.91 10.06 -8.96 -5.30 0.87 1.91
Operating Cash Flow Less CapEx to Interest Expense		 43.38 0.00 58.43 43.87 106.85 23.68 0.38 -26.94 -12.49 -0.31 -0.07
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.00 1.06 1.12 1.04 0.96 0.80 0.93 0.99 1.08 0.88 0.94
Accounts Receivable Turnover		 6.54 6.96 7.15 6.42 5.59 5.11 6.15 5.71 7.07 6.08 6.08
Inventory Turnover		 1.47 1.45 1.29 1.22 1.26 1.22 1.37 1.35 1.62 1.23 1.42
Fixed Asset Turnover		 7.86 8.10 9.22 10.30 8.71 6.44 7.56 7.84 6.86 5.35 6.11
Accounts Payable Turnover		 5.84 5.72 5.73 5.35 5.31 4.74 4.64 4.57 6.06 4.73 4.78
Days Sales Outstanding (DSO)		 55.79 52.41 51.02 56.87 65.29 71.48 59.32 63.94 51.66 59.99 60.02
Days Inventory Outstanding (DIO)		 247.64 251.17 283.79 298.75 288.87 299.18 266.19 270.51 225.92 296.21 257.61
Days Payable Outstanding (DPO)		 62.46 63.87 63.68 68.18 68.70 77.03 78.74 79.85 60.25 77.11 76.33
Cash Conversion Cycle (CCC)		 240.96 239.72 271.14 287.44 285.45 293.63 246.78 254.60 217.33 279.09 241.30
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 227 210 215 263 257 260 249 286 655 574 522
Invested Capital Turnover		 1.74 1.88 2.04 1.89 1.77 1.57 1.82 1.72 1.58 1.30 1.50
Increase / (Decrease) in Invested Capital		 -1.74 -17 5.92 48 -5.98 2.82 -11 37 369 -81 -52
Enterprise Value (EV)		 677 591 916 921 810 734 526 360 552 738 673
Market Capitalization		 741 645 997 993 880 831 614 411 495 667 600
Book Value per Share		 $15.37 $14.78 $16.27 $17.73 $17.19 $18.46 $17.06 $16.84 $16.29 $13.17 $11.36
Tangible Book Value per Share		 $12.25 $11.36 $12.76 $11.16 $10.62 $10.98 $10.78 $10.90 $7.79 $5.48 $4.60
Total Capital		 290 263 297 335 328 357 337 337 693 660 607
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 94 157 157
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 93 157 157
Net Debt		 -64 -54 -81 -72 -70 -97 -88 -51 57 71 72
Capital Expenditures (CapEx)		 22 16 15 14 19 15 18 23 62 35 35
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 67 57 91 87 105 70 76 122 219 179 161
Debt-free Net Working Capital (DFNWC)		 130 111 172 159 176 166 164 172 256 265 246
Net Working Capital (NWC)		 130 111 172 159 176 166 164 172 255 265 246
Net Nonoperating Expense (NNE)		 0.26 0.82 1.95 4.35 15 -6.90 33 10 54 67 35
Net Nonoperating Obligations (NNO)		 -64 -54 -81 -72 -70 -97 -88 -51 57 71 72
Total Depreciation and Amortization (D&A)		 23 22 22 20 28 34 33 32 97 88 83
Debt-free, Cash-free Net Working Capital to Revenue		 16.80% 13.91% 21.03% 19.10% 22.89% 17.13% 16.33% 26.41% 29.35% 22.38% 19.61%
Debt-free Net Working Capital to Revenue		 32.85% 27.07% 39.74% 35.04% 38.19% 40.95% 35.24% 37.41% 34.41% 33.10% 29.96%
Net Working Capital to Revenue		 32.85% 27.07% 39.74% 35.04% 38.19% 40.95% 35.24% 37.41% 34.24% 33.10% 29.96%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.15) $0.17 $0.34 $0.73 ($1.51) $0.13 ($1.95) ($0.98) ($4.12) ($3.30) ($2.33)
Adjusted Weighted Average Basic Shares Outstanding		 18.37M 18.14M 18.12M 18.49M 18.90M 19.27M 19.69M 20.05M 36.73M 38.13M 39.60M
Adjusted Diluted Earnings per Share		 ($0.15) $0.17 $0.34 $0.72 ($1.51) $0.13 ($1.95) ($0.98) ($4.12) ($3.30) ($2.33)
Adjusted Weighted Average Diluted Shares Outstanding		 18.37M 18.46M 18.50M 18.91M 18.90M 19.39M 19.69M 20.05M 36.73M 38.13M 39.60M
Adjusted Basic & Diluted Earnings per Share		 ($0.15) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 18.80M 17.95M 18.41M 19.06M 19.18M 19.51M 19.85M 36.46M 37.41M 39.02M 40.14M
Normalized Net Operating Profit after Tax (NOPAT)		 6.48 25 29 18 -13 -4.39 -5.82 -9.29 -97 -59 -57
Normalized NOPAT Margin		 1.63% 6.05% 6.59% 4.01% -2.86% -1.08% -1.25% -2.02% -13.07% -7.41% -6.93%
Pre Tax Income Margin		 2.15% 4.64% 8.39% 5.05% -5.88% -0.09% -2.91% -3.84% -19.94% -15.49% -11.04%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 18.40 0.00 88.48 28.64 -220.71 0.85 -6.35 -12.75 -16.23 -3.18 -4.19
NOPAT to Interest Expense		 -5.21 0.00 19.66 21.93 -107.78 -1.77 -3.17 -7.21 -11.28 -2.00 -3.26
EBIT Less CapEx to Interest Expense		 -27.40 0.00 53.23 12.22 -376.43 -5.38 -16.03 -30.73 -23.42 -4.36 -6.17
NOPAT Less CapEx to Interest Expense		 -51.01 0.00 -15.60 5.52 -263.49 -8.00 -12.85 -25.19 -18.47 -3.18 -5.24
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -17.77% 0.00% 0.00%
Augmented Payout Ratio		 -412.07% 2,075.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -17.77% 0.00% 0.00%

Quarterly Metrics And Ratios for Orthofix Medical

This table displays calculated financial ratios and metrics derived from Orthofix Medical's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 39,022,492.00 39,180,833.00 39,494,265.00 39,599,659.00 40,144,397.00
DEI Adjusted Shares Outstanding		 - - - - - - 39,022,492.00 39,180,833.00 39,494,265.00 39,599,659.00 40,144,397.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -1.36 -0.36 -0.58 -0.06 -0.52
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 61.41% 62.88% 7.65% 6.20% 6.85% 8.33% 2.67% 2.27% 4.59% 1.97% 1.58%
EBITDA Growth		 -497.15% 361.37% 66.02% 27.94% 65.42% 141.10% -6.42% 187.48% -92.09% 10.68% 94.82%
EBIT Growth		 -194.77% -159.68% 48.15% 25.20% 20.08% 15.72% -55.59% 62.53% 17.95% 114.60% 68.15%
NOPAT Growth		 -322.48% -65.84% 50.87% 32.01% 22.70% 37.34% -66.59% 35.75% 9.80% 104.30% 70.46%
Net Income Growth		 -169.29% -213.99% 40.89% 15.18% 5.09% -31.44% -47.40% 57.90% 16.77% 92.38% 60.62%
EPS Growth		 -45.28% -62.86% 44.44% 17.76% 7.79% -33.33% -42.11% 59.09% 19.72% 93.42% 61.48%
Operating Cash Flow Growth		 137.74% -385.09% 45.34% 262.87% 2,346.75% 454.50% 1.10% 29.55% 6.26% 16.72% 4.25%
Free Cash Flow Firm Growth		 -8,876.44% -752.59% 95.34% 100.20% 106.91% 119.08% 443.81% 9,520.57% 147.21% -28.07% -87.21%
Invested Capital Growth		 131.24% 129.01% -0.02% -2.79% -6.13% -12.35% -15.83% -13.92% -12.76% -9.07% -3.44%
Revenue Q/Q Growth		 -1.61% 8.19% -5.26% 5.31% -1.01% 9.69% -10.21% 4.89% 1.24% 6.94% -10.55%
EBITDA Q/Q Growth		 62.43% 240.10% -274.02% 21.34% 81.97% 1,076.82% -176.81% 164.66% -139.59% 662.85% -103.60%
EBIT Q/Q Growth		 26.86% 34.54% -74.43% 10.44% 21.84% 30.97% -222.02% 78.43% -71.14% 112.28% -802.64%
NOPAT Q/Q Growth		 33.26% 25.09% -60.18% 15.10% 24.12% 39.27% -325.83% 67.26% -6.52% 102.90% -3,022.27%
Net Income Q/Q Growth		 26.81% 23.16% -62.44% 7.15% 18.11% -6.42% -82.17% 73.48% -61.88% 90.25% -840.95%
EPS Q/Q Growth		 28.04% 25.97% -66.67% 7.37% 19.32% -7.04% -77.63% 73.33% -58.33% 91.23% -940.00%
Operating Cash Flow Q/Q Growth		 108.65% -1,503.35% -177.79% 148.31% 29.91% 103.32% -177.50% 163.29% 6.56% 123.33% -163.58%
Free Cash Flow Firm Q/Q Growth		 2.41% 1.31% 94.66% 103.94% 3,232.80% 172.45% -3.82% 10.16% -14.36% -20.73% -82.89%
Invested Capital Q/Q Growth		 -0.24% 0.54% 0.57% -3.63% -3.67% -6.12% -3.43% -1.45% -2.37% -2.14% 2.55%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 65.09% 68.63% 67.46% 67.84% 68.69% 69.02% 62.80% 68.69% 72.23% 71.09% 70.94%
EBITDA Margin		 -2.50% 3.24% -5.95% -4.45% -0.81% 7.21% -6.17% 3.80% -1.49% 7.83% -0.31%
Operating Margin		 -13.29% -9.20% -15.55% -12.54% -9.61% -5.32% -25.24% -7.88% -8.29% 0.22% -7.34%
EBIT Margin		 -14.57% -8.82% -16.23% -13.80% -10.90% -6.86% -24.59% -5.06% -8.55% 0.98% -7.71%
Profit (Net Income) Margin		 -15.68% -11.14% -19.10% -16.84% -13.93% -13.52% -27.42% -6.93% -11.09% -1.01% -10.63%
Tax Burden Percent		 101.66% 100.95% 102.42% 103.35% 102.82% 98.10% 101.84% 99.00% 102.39% 101.37% 100.36%
Interest Burden Percent		 105.88% 125.17% 114.89% 118.03% 124.32% 200.88% 109.46% 138.45% 126.63% -101.53% 137.34%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -13.32% -10.20% -12.53% -10.50% -8.34% -4.84% -23.42% -7.55% -8.29% 0.24% -7.78%
ROIC Less NNEP Spread (ROIC-NNEP)		 139.95% -327.26% -49.50% -41.72% -31.50% -37.86% -43.82% -10.79% -20.55% -3.34% -18.75%
Return on Net Nonoperating Assets (RNNOA)		 -2.26% -2.06% -3.36% -3.61% -3.37% -4.39% -7.89% -1.91% -3.76% -0.50% -4.13%
Return on Equity (ROE)		 -15.58% -12.26% -15.89% -14.10% -11.71% -9.24% -31.31% -9.46% -12.05% -0.27% -11.91%
Cash Return on Invested Capital (CROIC)		 -99.01% -99.11% -11.53% -7.71% -3.80% 3.53% 5.18% 3.68% 2.22% -0.90% -2.53%
Operating Return on Assets (OROA)		 -14.37% -9.49% -13.51% -11.93% -9.62% -6.03% -22.89% -4.76% -8.23% 0.93% -7.45%
Return on Assets (ROA)		 -15.47% -12.00% -15.89% -14.55% -12.30% -11.88% -25.51% -6.52% -10.67% -0.95% -10.26%
Return on Common Equity (ROCE)		 -15.58% -12.26% -15.89% -14.10% -11.71% -9.24% -31.31% -9.46% -12.05% -0.27% -11.91%
Return on Equity Simple (ROE_SIMPLE)		 -22.14% 0.00% -22.18% -22.07% -22.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -17 -13 -21 -17 -13 -8.03 -34 -11 -12 0.35 -10
NOPAT Margin		 -9.30% -6.44% -10.89% -8.78% -6.73% -3.73% -17.67% -5.52% -5.80% 0.16% -5.14%
Net Nonoperating Expense Percent (NNEP)		 -153.27% 317.07% 36.97% 31.23% 23.16% 33.02% 20.40% 3.24% 12.26% 3.58% 10.97%
Return On Investment Capital (ROIC_SIMPLE)		 - -1.85% - - - -1.22% -5.56% -1.82% -1.99% 0.06% -1.54%
Cost of Revenue to Revenue		 34.91% 32.04% 32.54% 32.16% 31.31% 30.98% 37.20% 31.31% 27.77% 28.91% 29.06%
SG&A Expenses to Revenue		 14.75% 211.11% 16.78% 17.12% 17.07% 200.93% 68.67% 67.20% 72.02% 62.19% 68.58%
R&D to Revenue		 10.09% 9.51% 10.33% 9.09% 8.80% 8.72% 10.21% 7.84% 7.18% 6.99% 7.79%
Operating Expenses to Revenue		 78.37% 77.83% 83.02% 80.38% 78.30% 74.34% 88.04% 76.57% 80.52% 70.87% 78.28%
Earnings before Interest and Taxes (EBIT)		 -27 -18 -31 -27 -21 -15 -48 -10 -18 2.16 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.60 6.45 -11 -8.83 -1.59 16 -12 7.72 -3.06 17 -0.62
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.77 0.83 0.95 0.91 1.13 1.33 1.39 0.95 1.31 1.33 1.06
Price to Tangible Book Value (P/TBV)		 1.58 1.73 2.07 2.05 2.63 3.19 3.49 2.37 3.36 3.29 2.69
Price to Revenue (P/Rev)		 0.71 0.66 0.72 0.65 0.76 0.83 0.79 0.54 0.71 0.73 0.56
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.78 0.84 0.96 0.92 1.12 1.29 1.32 0.96 1.25 1.29 1.05
Enterprise Value to Revenue (EV/Rev)		 0.76 0.74 0.83 0.76 0.87 0.92 0.91 0.65 0.82 0.82 0.68
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 53.94 80.93 67.71 26.39
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 28.64 28.19 18.33 22.79 20.17 16.44
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 34.04 23.33 24.14 52.73 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.11 0.16 0.21 0.22 0.23 0.31 0.34 0.34 0.36 0.35 0.51
Long-Term Debt to Equity		 0.11 0.16 0.20 0.21 0.21 0.31 0.34 0.34 0.36 0.35 0.51
Financial Leverage		 -0.02 0.01 0.07 0.09 0.11 0.12 0.18 0.18 0.18 0.15 0.22
Leverage Ratio		 1.43 1.48 1.48 1.50 1.55 1.65 1.68 1.71 1.76 1.83 1.91
Compound Leverage Factor		 1.51 1.85 1.70 1.77 1.93 3.32 1.84 2.37 2.22 -1.86 2.63
Debt to Total Capital		 10.21% 13.61% 17.17% 17.77% 18.38% 23.79% 25.50% 25.52% 26.22% 25.91% 33.71%
Short-Term Debt to Total Capital		 0.00% 0.18% 0.45% 0.71% 0.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 10.21% 13.43% 16.71% 17.07% 17.41% 23.79% 25.50% 25.52% 26.22% 25.91% 33.71%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 89.79% 86.39% 82.83% 82.23% 81.62% 76.21% 74.50% 74.48% 73.78% 74.09% 66.29%
Debt to EBITDA		 -1.44 -2.17 -5.46 -6.48 -7.80 -25.77 -23.02 16.13 19.01 15.85 10.41
Net Debt to EBITDA		 -0.75 -1.30 -4.10 -4.90 -5.65 -11.70 -14.15 9.07 11.03 7.28 4.73
Long-Term Debt to EBITDA		 -1.44 -2.14 -5.32 -6.22 -7.39 -25.77 -23.02 16.13 19.01 15.85 10.41
Debt to NOPAT		 -0.76 -0.97 -1.55 -1.74 -1.85 -2.65 -2.15 -2.36 -2.40 -2.76 -6.73
Net Debt to NOPAT		 -0.39 -0.58 -1.17 -1.31 -1.34 -1.20 -1.32 -1.33 -1.40 -1.27 -3.05
Long-Term Debt to NOPAT		 -0.76 -0.96 -1.51 -1.67 -1.75 -2.65 -2.15 -2.36 -2.40 -2.76 -6.73
Altman Z-Score		 1.74 1.76 1.74 1.62 1.78 1.79 1.63 1.40 1.52 1.62 1.28
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.58 2.54 2.65 2.48 2.39 2.57 2.71 2.67 2.47 2.45 2.87
Quick Ratio		 0.97 0.98 1.01 0.97 0.96 1.29 1.32 1.32 1.21 1.28 1.60
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -387 -382 -20 0.80 27 73 70 77 66 52 8.97
Operating Cash Flow to CapEx		 2.18% -40.93% -176.37% 96.15% 219.30% 245.47% -273.03% 163.72% 125.22% 254.64% -165.18%
Free Cash Flow to Firm to Interest Expense		 -245.59 -84.89 -4.47 0.16 5.14 4.89 15.56 19.55 14.13 12.05 1.58
Operating Cash Flow to Interest Expense		 0.30 -1.49 -4.08 1.82 2.24 1.59 -4.08 2.95 2.65 6.37 -3.11
Operating Cash Flow Less CapEx to Interest Expense		 -13.58 -5.12 -6.39 -0.07 1.22 0.94 -5.58 1.15 0.53 3.87 -4.99
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.99 1.08 0.83 0.86 0.88 0.88 0.93 0.94 0.96 0.94 0.97
Accounts Receivable Turnover		 7.05 7.07 6.35 6.48 6.55 6.08 6.25 6.35 6.40 6.08 6.12
Inventory Turnover		 1.43 1.62 1.16 1.17 1.17 1.23 1.34 1.38 1.37 1.42 1.37
Fixed Asset Turnover		 6.35 6.86 5.14 5.23 5.23 5.35 5.57 5.71 5.91 6.11 6.45
Accounts Payable Turnover		 5.65 6.06 4.99 4.98 5.00 4.73 5.17 5.53 5.32 4.78 4.84
Days Sales Outstanding (DSO)		 51.81 51.66 57.47 56.31 55.70 59.99 58.41 57.50 57.03 60.02 59.62
Days Inventory Outstanding (DIO)		 255.92 225.92 313.34 311.66 311.40 296.21 271.79 264.80 267.10 257.61 266.31
Days Payable Outstanding (DPO)		 64.58 60.25 73.20 73.29 73.07 77.11 70.66 65.99 68.57 76.33 75.49
Cash Conversion Cycle (CCC)		 243.14 217.33 297.61 294.68 294.04 279.09 259.53 256.31 255.56 241.30 250.44
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 652 655 659 635 612 574 555 547 534 522 536
Invested Capital Turnover		 1.43 1.58 1.15 1.20 1.24 1.30 1.33 1.37 1.43 1.50 1.51
Increase / (Decrease) in Invested Capital		 370 369 -0.14 -18 -40 -81 -104 -88 -78 -52 -19
Enterprise Value (EV)		 509 552 632 587 682 738 733 525 669 673 561
Market Capitalization		 472 495 543 498 596 667 636 437 578 600 460
Book Value per Share		 $16.75 $16.29 $15.25 $14.55 $13.78 $13.17 $11.74 $11.70 $11.20 $11.36 $10.84
Tangible Book Value per Share		 $8.16 $7.79 $7.02 $6.47 $5.93 $5.48 $4.67 $4.71 $4.35 $4.60 $4.26
Total Capital		 685 693 689 664 644 660 615 615 600 607 657
Total Debt		 70 94 118 118 118 157 157 157 157 157 221
Total Long-Term Debt		 70 93 115 113 112 157 157 157 157 157 221
Net Debt		 36 57 89 89 86 71 96 88 91 72 100
Capital Expenditures (CapEx)		 22 16 11 9.34 5.32 9.67 6.74 7.11 9.90 11 11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 208 219 222 206 198 179 186 179 168 161 180
Debt-free Net Working Capital (DFNWC)		 241 256 251 235 231 265 246 247 234 246 300
Net Working Capital (NWC)		 241 255 248 230 224 265 246 247 234 246 300
Net Nonoperating Expense (NNE)		 12 9.35 15 16 14 21 19 2.88 11 2.57 11
Net Nonoperating Obligations (NNO)		 36 57 89 89 86 71 96 88 91 72 100
Total Depreciation and Amortization (D&A)		 22 24 19 19 20 30 36 18 15 15 15
Debt-free, Cash-free Net Working Capital to Revenue		 31.04% 29.35% 29.26% 26.73% 25.29% 22.38% 23.09% 22.10% 20.58% 19.61% 21.76%
Debt-free Net Working Capital to Revenue		 36.08% 34.41% 33.15% 30.48% 29.45% 33.10% 30.60% 30.59% 28.64% 29.96% 36.41%
Net Working Capital to Revenue		 36.08% 34.24% 32.73% 29.87% 28.65% 33.10% 30.60% 30.59% 28.64% 29.96% 36.41%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.77) ($0.57) ($0.95) ($0.88) ($0.71) ($0.76) ($1.35) ($0.36) ($0.57) ($0.05) ($0.52)
Adjusted Weighted Average Basic Shares Outstanding		 37.25M 36.73M 37.74M 38.02M 38.49M 38.13M 39.19M 39.50M 39.77M 39.60M 40.45M
Adjusted Diluted Earnings per Share		 ($0.77) ($0.57) ($0.95) ($0.88) ($0.71) ($0.76) ($1.35) ($0.36) ($0.57) ($0.05) ($0.52)
Adjusted Weighted Average Diluted Shares Outstanding		 37.25M 36.73M 37.74M 38.02M 38.49M 38.13M 39.19M 39.50M 39.77M 39.60M 40.45M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 36.76M 37.41M 37.53M 38.17M 38.21M 39.02M 39.18M 39.49M 39.60M 40.14M 40.42M
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -13 -21 -17 -13 -8.03 -34 -11 -12 0.35 -10
Normalized NOPAT Margin		 -9.30% -6.44% -10.89% -8.78% -6.73% -3.73% -17.67% -5.52% -5.80% 0.16% -5.14%
Pre Tax Income Margin		 -15.43% -11.03% -18.65% -16.29% -13.55% -13.78% -26.92% -7.00% -10.83% -1.00% -10.59%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -17.01 -3.90 -6.72 -5.55 -4.11 -0.99 -10.57 -2.60 -3.76 0.50 -2.68
NOPAT to Interest Expense		 -10.86 -2.85 -4.51 -3.53 -2.54 -0.54 -7.59 -2.84 -2.55 0.08 -1.78
EBIT Less CapEx to Interest Expense		 -30.89 -7.53 -9.03 -7.44 -5.13 -1.64 -12.06 -4.40 -5.87 -2.00 -4.56
NOPAT Less CapEx to Interest Expense		 -24.74 -6.48 -6.82 -5.42 -3.56 -1.19 -9.09 -4.64 -4.66 -2.42 -3.67
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% -17.77% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -17.77% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Orthofix Medical’s latest quarter shows a company still struggling to reach profitability, but there are signs of improved liquidity and stronger operating cash flow versus earlier periods. In Q1 2026, revenue slipped modestly year over year while losses remained sizable. At the same time, the balance sheet improved meaningfully in cash and total equity, helped by debt financing. For retail investors, the key question is whether Orthofix can turn its gross profit into sustainable operating profit before the balance sheet becomes more strained.

  • Cash and equivalents rose to $120.3 million in Q1 2026 from $62.9 million in Q3 2025, giving the company a stronger near-term liquidity cushion.
  • Total equity increased to $435.2 million in Q1 2026, up from $442.5 million in Q3 2025 and higher than earlier 2025 periods after accounting for financing activity.
  • Gross profit remained solid at $139.5 million in Q1 2026, showing the core business still generates healthy margin dollars.
  • Operating cash flow improved sharply sequentially from negative $27.7 million in Q4 2025 to negative $17.6 million in Q1 2026.
  • The company generated strong financing inflow in Q1 2026, including $64.0 million from debt issuance, which supported the cash balance.
  • Revenue in Q1 2026 was $196.7 million, slightly below $205.6 million in Q3 2025 and $219.9 million in Q4 2025.
  • Gross profit margin remained fairly stable, but operating expenses were still too high to produce profitability.
  • Inventory stayed elevated at $177.8 million, which may reflect ongoing working-capital needs and possible demand normalization risk.
  • Long-term debt increased to $221.3 million from $157.2 million in Q3 2025, indicating a more leveraged capital structure.
  • Orthofix reported an operating loss of $14.4 million in Q1 2026, extending a long streak of negative operating results.
  • Net loss widened to $20.9 million in Q1 2026, or -$0.52 per share, versus a -$2.2 million loss in Q4 2025 and -$14.1 million in Q2 2025.
  • Selling, general and administrative expense remained very heavy at $134.9 million, limiting operating leverage.
  • The company has a history of large quarterly losses, including -$53.1 million in Q1 2025 and -$36.0 million in Q1 2024, showing profitability has been a persistent challenge.

Bottom line: Orthofix appears to have stabilized its liquidity somewhat, but the business is still not producing consistent profits. The improving cash position is encouraging, yet higher debt and continued operating losses mean investors should watch for evidence of expense control and revenue growth before expecting a sustained turnaround.

07/13/26 11:13 PM ETAI Generated. May Contain Errors.

Orthofix Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Orthofix Medical's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Orthofix Medical's net income appears to be on an upward trend, with a most recent value of -$92.19 million in 2025, rising from -$2.81 million in 2015. The previous period was -$126.00 million in 2024. View Orthofix Medical's forecast to see where analysts expect Orthofix Medical to go next.

Orthofix Medical's total operating income in 2025 was -$81.43 million, based on the following breakdown:
  • Total Gross Profit: $566.02 million
  • Total Operating Expenses: $647.45 million

Over the last 10 years, Orthofix Medical's total revenue changed from $396.49 million in 2015 to $822.31 million in 2025, a change of 107.4%.

Orthofix Medical's total liabilities were at $400.61 million at the end of 2025, a 2.7% increase from 2024, and a 264.5% increase since 2015.

In the past 10 years, Orthofix Medical's cash and equivalents has ranged from $33.11 million in 2023 to $96.29 million in 2020, and is currently $82.03 million as of their latest financial filing in 2025.

Over the last 10 years, Orthofix Medical's book value per share changed from 15.37 in 2015 to 11.36 in 2025, a change of -26.1%.


Related Companies

Financial statements for NASDAQ:OFIX last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
Print this and keep it by your screen
Ever been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...
Profits Run | Sponsoredtc pixel
Your money is changing
Porter Stansberry - who warned readers about Fannie Mae in 2006, called gold in 2008, and predicted COVID-era ...
Porter & Company | Sponsoredtc pixel
The $5 company SpaceX can’t survive without
The investors who got rich on AI didn't all buy Nvidia. Some bought ASML, the company that makes the machines ...
Traders Agency | Sponsoredtc pixel